Across Germany, Austria, and Luxembourg, a quiet but consequential shift is unfolding in how medicine approaches childhood metabolic disease. Over six years, the share of young people with type 2 diabetes receiving GLP-1 receptor agonist drugs has grown more than fourfold, and real-world evidence now confirms what clinical trials suggested: these medications are delivering meaningful improvements in weight, blood sugar, and blood pressure for children who had long struggled despite conventional efforts. The findings, presented in Milan, invite a broader reckoning with how societies weigh the r
GLP-1 drugs show real-world benefits in European children with type 2 diabetes
Approximately 200,000 young people in Germany live with extreme obesity and face severe complications including sleep apnea, depression, and type 2 diabetes.
Many of these children had gained weight for years, despite lifestyle changes.
Mark
So these drugs have been approved for kids since 2019, but we're only now seeing real-world data on whether they actually work. Why the lag?
Mimi
Clinical trials are tightly controlled—everyone takes the drug exactly as prescribed, visits happen on schedule, side effects get monitored closely. Real life is messier. Kids miss appointments, they stop taking medications, they're on other drugs too. The researchers wanted to know if the benefits held up in that messier reality.
Luke
And did they? The 2.3 percent average BMI reduction—is that actually significant, or is that the kind of number that sounds good in a press release?
Mimi
Auzanneau makes a fair point: these kids had been gaining weight for years despite diet and exercise. A 2.3 percent reduction in that context means the medication is actually reversing a long trend. And 37 percent hit at least 5 percent reduction, which is more substantial.
Mark
What about side effects? The source doesn't really address that.
Luke
Right. We know concerns about side effects are one reason doctors aren't prescribing these more widely, but the study doesn't tell us what side effects actually occurred in these 240 kids, how often, or how serious.
Mimi
That's a real gap. The study was designed to measure weight, blood pressure, and blood sugar. It wasn't designed to catalog adverse events. You'd need a different kind of study to answer that.
Mark
And the kids in this study—are they representative of all kids with type 2 diabetes, or just the ones in Germany, Austria, and Luxembourg?
Luke
Just those three countries, and specifically the ones in this registry. Forty-seven percent had a migration background, which tells you something about the population. You can't automatically assume these results apply to, say, children in the United States or Asia.
Mimi
Fair. But it's still the largest real-world evidence we have for this age group in any region. That's why it matters.
Mark
What happens next? Do we expect these drugs to become standard treatment?
Mimi
The researchers think so. As insurance coverage expands and as doctors get more comfortable prescribing them, use will likely keep climbing. But there's still a lot we don't know about long-term effects in children.
El Pulso
- Some 200,000 young people in Germany alone carry the weight of extreme obesity, along with its companions — sleep apnea, depression, and diabetes — making the search for effective treatment a matter of genuine urgency.
- GLP-1 prescriptions for young patients with type 2 diabetes surged from 6.3% to 27.2% in just six years, signaling a rapid reshaping of pediatric diabetes care across three European countries.
- Real-world data from nearly 1,900 patients cut through the uncertainty: more than a third of treated children achieved at least a 5% BMI reduction, and hypertension rates dropped from 60% to 52% — gains that held after controlling for age, sex, and background.
- Researchers caution that even this rising adoption likely understates the drugs' potential, with insurance gaps and lingering fears about side effects still keeping many eligible children from access.
- The trajectory points upward — as coverage expands and clinical familiarity grows, GLP-1 use in pediatric populations is expected to climb further, though whether benefits will scale equitably beyond well-resourced healthcare systems remains an open question.
Across Germany, Austria, and Luxembourg, a quiet but consequential shift is unfolding in how medicine approaches childhood metabolic disease. Over six years, the share of young people with type 2 diabetes receiving GLP-1 receptor agonist drugs has grown more than fourfold, and real-world evidence now confirms what clinical trials suggested: these medications are delivering meaningful improvements in weight, blood sugar, and blood pressure for children who had long struggled despite conventional efforts. The findings, presented in Milan, invite a broader reckoning with how societies weigh the risks of intervention against the slower, less visible harms of untreated obesity in the young.
Researchers tracking nearly 1,900 children and young people across Germany, Austria, and Luxembourg have documented a striking transformation in pediatric diabetes care. Between 2019 and 2025, the proportion of young patients prescribed GLP-1 receptor agonist drugs — including semaglutide, liraglutide, and tirzepatide — rose from just over 6 percent to more than 27 percent. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.
The backdrop is sobering. Around 200,000 young people in Germany alone live with extreme obesity, often alongside serious complications such as sleep apnea, depression, and type 2 diabetes. European regulators had approved GLP-1 drugs for type 2 diabetes in children as young as ten in 2019, later expanding their use for obesity management to children as young as six — yet concrete evidence of real-world effectiveness in pediatric populations remained scarce. Dr. Marie Auzanneau of Ulm University led the study to fill that gap.
The adoption curve was consistent across age groups, with liraglutide emerging as the most commonly prescribed option. Auzanneau noted that even the rising numbers likely understate the drugs' potential, citing insurance barriers and concerns about side effects as factors holding back wider use.
To assess whether the medications actually worked, researchers examined 240 young people with documented GLP-1 use across at least two clinic visits, with a median treatment duration of eleven months. The results were concrete: more than a third achieved at least a 5 percent BMI reduction, a quarter reached 10 percent, and the rate of high blood pressure fell from 60 to 52 percent — all while blood sugar control improved measurably. These gains held after adjusting for sex, age, migration background, and starting weight.
Auzanneau was careful to frame the significance beyond the scale. Better weight management, she noted, should reduce these children's risk of depression, sleep apnea, and the long-term cardiovascular and organ damage that poorly controlled diabetes can bring. Researchers expect prescriptions to keep climbing as insurance coverage broadens and families grow more comfortable with these medications — though whether the benefits documented in three relatively wealthy European healthcare systems will extend equitably to far larger populations remains the defining question ahead.
Researchers tracking the health of nearly 1,900 children and young people across Germany, Austria, and Luxembourg have documented a striking shift in how doctors are treating type 2 diabetes in this age group. Between 2019 and 2025, the proportion of young patients prescribed GLP-1 receptor agonist drugs—medications like semaglutide, liraglutide, and tirzepatide—climbed from just over 6 percent to more than 27 percent. The data comes from the Diabetes Prospective Follow-up registry, a multi-country tracking system, and was presented at the annual meeting of the European Association for the Study of Diabetes in Milan in late September.
The context matters. European regulators approved these drugs for type 2 diabetes in children as young as ten in 2019, then expanded their use for weight management in children with obesity starting at age twelve in 2021, later lowering that threshold to age six. Yet until now, little concrete evidence existed about whether these medications actually worked in real children living real lives—outside the controlled conditions of clinical trials. About 200,000 young people in Germany alone live with extreme obesity, often shadowed by serious complications: sleep apnea, depression, and type 2 diabetes itself. Dr. Marie Auzanneau of Ulm University led the research to understand how often these drugs were being used and whether they delivered measurable benefits.
The numbers tell a story of accelerating adoption. In 2019, about 6.3 percent of the 448 young people with type 2 diabetes in the registry were taking GLP-1 drugs. By 2025, that figure had climbed to 27.2 percent of 611 patients. The increase was consistent across age groups: 14 percent of children aged 6 to 12, 28 percent of those 12 to 18, and 29 percent of those 18 to 24. Liraglutide emerged as the most frequently prescribed option, used by nearly 12 percent of all young people with type 2 diabetes in 2025. Auzanneau noted that even this rising trend likely understates the true potential. "GLP-1 receptor agonists are probably still underused," she said, pointing to lingering concerns about side effects and gaps in insurance coverage as explanations for the gap between current use and what might eventually become standard practice.
The real question was whether the drugs actually helped. To answer it, researchers focused on 240 young people who had documented GLP-1 use at two or more clinic visits, with a median treatment duration of eleven months. At the start, 19 percent were overweight, 44 percent obese, and 32 percent severely obese. The results were concrete. More than a third achieved at least a 5 percent reduction in BMI adjusted for age, and a quarter reached a 10 percent reduction. The average improvement across the group was 2.3 percent—a figure that sounds modest until you consider that many of these children had gained weight year after year despite diet and exercise efforts. Blood sugar control improved measurably, and the proportion of young people with high blood pressure fell from 60 percent to 52 percent. These improvements held up even after researchers adjusted for sex, age, migration background, and starting weight.
Auzanneau framed the significance beyond the numbers. "This isn't just about weight loss," she said. By helping young people reach healthier weights, the drugs should reduce their risk of depression, sleep apnea, and other obesity-linked conditions. Better blood sugar control, in turn, lowers the risk of heart disease and damage to the eyes, kidneys, and nerves—complications that can diminish both the quality and length of life. The researchers expect use to continue climbing as insurance barriers fall away and as doctors and families grow more comfortable with these medications in younger populations. What remains to be seen is whether the real-world benefits documented in these three European countries will hold as the drugs reach far larger numbers of children, and whether access will expand beyond the relatively wealthy healthcare systems where this study was conducted.
Citas Notables
A reduction of 2.3% is meaningful when we consider that many of these children and young people had gained weight for years, despite making lifestyle changes.— Dr. Marie Auzanneau, Ulm University
This isn't just about weight loss. By helping children, adolescents and young adults reach a healthier weight, these drugs should reduce their likelihood of developing depression, sleep apnoea and other severe conditions that are linked to obesity.— Dr. Marie Auzanneau
Quieres la nota completa?
Lee el original en News-Medical ↗